IgAN is a serious, immune-mediated, progressive disease with an average age at diagnosis of ~35 years old, leading to severe impact on quality of life2
BAFF = B-cell activating factor; APRIL = A proliferation-inducing ligand; ; TACI = transmembrane activator and calcium-modulator and cyclophilin ligand interactor.
1Cheung CK, et al. Front Nephrol 2023; 2Dillon SR, et al. Arthritis Res Ther 2010; 3Vera data on file; 4Willen D, et al. Eur J Drug Metab Pharmacokinet 2020; 5Gordon C, et al. Rheumatol Adv Pract 2019 and data on file; 6Lafayette R, et al. Kidney Int 2024; 7Lafayette R, et al. ERA 2024, abstr 812.
Multinational, randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating the safety and efficacy of ataciceptin patients with IgAN who continue to have persistent proteinuriaand remain at high risk of disease progression.
1Lafayette R, et al. Kidney Int 2024; 2Floege J, et al. ERA 2024, abstr 123; 3Lafayette R, et al. ERA 2024, abstr 812; 4Mean ± SE; 5Change from baseline in number of participants with hematuria at each visit divided by number with baseline hematuria. 72-week atacicept data includes participants originally randomized to any atacicept dose (25 mg, 75 mg, 150 mg) during the double-blind period in the intent-to-treat population for Gd-IgA1, hematuria, and eGFR, and week 36 per-protocol population for UPCR.
Participants who switched from placebo to atacicept showed similar results to 36-week outcomes in participants originally randomized to atacicept
For more information, contact MEDINFO@VERATX.COM
BAFF is also known as B Lymphocyte Stimulator or BLyS.
Watch this video to learn about atacicept’s mechanism of action in IgAN and 36-week results from the ORIGIN Phase 2b clinical trial of atacicept in IgAN
Multinational, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the safety and efficacy of atacicept 150 mg in adults with IgAN who continue to have persistent proteinuria and remain at high risk of disease progression.
Currently recruiting—learn more at theORIGINiganstudy.com or clinicaltrials.gov, or contact clinicaltrials@veratx.com